Antares Pharma files Otrexup at FDA for Rheumatoid Arthritis

Antares Pharma has submitted a New Drug Application (NDA) to the FDA for Otrexup, a combination product for the delivery of methotrexate (MTX) using Medi-Jet technology. Otrexup was developed for easy subcutaneous administration of MTX to enhance the treatment of rheumatoid arthritis (RA), poly-articular-course juvenile RA and moderate to severe psoriasis.